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Long-term efficacy of proton beam therapy (PBT) remains unclear for patients
with previously untreated hepatocellular carcinoma (HCC). We aimed to study
the long-term outcomes of PBT according to Barcelona Clinic Liver Cancer (BCLC)
staging classifications in patients with previously untreated HCC. The major eligi-
bility criteria of this observational study were an Eastern Cooperative Oncology
Group performance status (PS) 0–2, Child–Pugh grade A or B, previously
untreated HCC covered within an irradiation field, and no massive ascites. A total
of 66.0–77.0 GyE was administered in 10–35 fractions. Local tumor control (LTC),
defined as no progression in the irradiated field, progression-free survival (PFS),
and overall survival (OS) were assessed according to BCLC staging. From 2002 to
2009 at our institution, 129 patients were eligible. The 5-year LTC, PFS, and OS
rates were 94%, 28%, and 69% for patients with 0/A stage disease (n = 9/21),
87%, 23%, and 66% for patients with B stage disease (n = 34), and 75%, 9%,
and 25% for patients with C stage disease (n = 65), respectively. The 5-year LTC
and OS rates of 15 patients with tumor thrombi in major vessels were 90% and
34%, respectively. Multivariate analyses revealed that PS (0 versus 1–2) was a sig-
nificant prognostic factor for OS. No grade 3 or higher adverse effects were
observed. PBT showed favorable long-term efficacies with mild adverse effects in
BCLC stage 0 to C, and can be an alternative treatment for localized HCC
especially when accompanied with tumor thrombi. This study was registered
with UMIN Clinical Trials Registry (UMIN000025342).
H epatocellular carcinoma (HCC) is one of the most com-mon cancers worldwide.(1) Many treatment options are
currently available, including hepatectomy, liver transplanta-
tion, radiofrequency ablation (RFA), transcatheter arterial
chemoembolization (TACE) or radioembolization, and molecu-
lar targeted therapy.(2,3) Some new methods of radiation
therapy (RT), such as three-dimensional conformal RT,
intensity-modulated RT, and stereotactic body RT (SBRT),
have been used to treat HCC and demonstrated promising
results.(4–6) However, RT has not yet been accepted as a treat-
ment for HCC in the Barcelona Clinic Liver Cancer (BCLC)
staging and treatment strategy, and is considered a treatment
option only for patients who are not eligible for other estab-
lished local therapies.(7)
Proton beams, unlike conventional X-rays, form a unique
Bragg-peak ionization that enables “tumor-targeted radical
irradiation”.(8,9) Based on this unique property, we first used
proton beam therapy (PBT) to treat HCC in 1983 and reported
a 5-year local tumor control rate, indicating no progression
in the irradiated field, of over 80% and a 5-year survival
rate of 24–45% in patients with locoregional HCC,
retrospectively.(10–12) Recently, similar good local control of
HCC after PBT was reported from other facilities throughout
the world.(13–18) However, PBT efficacy and safety in the
BCLC staging remains unclear.
Thus, we aimed to study the long-term outcomes of PBT
according to BCLC staging classifications in patients with
untreated HCC.
Patients and Methods
Patients. Patients with HCC who were treated using PBT
were registered at the University of Tsukuba Hospital, Japan,
between January 2002 and December 2009. Eligibility criteria
for this study were age ≥ 20 years, Eastern Cooperative Oncol-
ogy Group performance status (PS) 0–2, Child–Pugh grade A
or B, no massive ascites, non-irradiated normal liver volume
≥ 500 mL, and previously untreated HCC diagnosed using
pathological findings of fine-needle biopsy or typical findings
of arterial enhancement and venous washout on dynamic com-
puted tomography (CT) or magnetic resonance imaging (MRI).
Solitary HCC and even multiple HCC with or without tumor
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thrombi were treated using PBT if all tumors could be covered
within the same irradiation field (≤ 135 mm in diameter).
Patient background information and laboratory results were
collected before PBT. These data included age, sex, PS, liver
disease etiology, comorbidity, blood cell counts, blood
biochemistry, tumor markers (alpha-fetoprotein [AFP] and
des-gamma-carboxy prothrombin [DCP]), tumor status, and
Child–Pugh grade.
This study was approved by the ethics committee of the
University of Tsukuba Hospital and conducted in accordance
with the ethical standards of the Declaration of Helsinki. All
patients were explained about standard therapies and PBT for
HCC in detail,(11) and provided written informed consent for
this study.
Proton beam irradiation. Before the start of treatment, metal-
lic fiducial markers were implanted percutaneously into the
hepatic parenchyma adjacent to the tumors under ultrasound
guidance. Custom-made body casts (ESFORM; Engineering
System, Matsumoto, Japan) were used to ensure adequate
immobilization of each patient during PBT. Treatment plan-
ning was performed on respiratory-synchronized CT images
taken at 5-mm intervals in the treatment position. The clinical
target volume was defined as the gross tumor volume plus 5-
to 10-mm margins in all directions. The planning target
volume was defined as the clinical target volume plus 8- to
10-mm margins in all directions and an additional 5-mm mar-
gin in the caudal direction for respiratory movement. The clin-
ical target volume was homogeneously covered with more
than 90% of the prescribed dose using the proton beam
spread-out Bragg peaks.(8) The treatment planning system auto-
matically derived the settings required for beam delivery
including ridge filters, the range shifter, the collimator, and a
bolus. Proton dosimetry was verified using a plastic phantom
for each patient prior to treatment initiation.(19)
Proton beams of 155–250 MeV generated by an accelerator
with a synchrotron were used for treatment. Beams were deliv-
ered using a rotation gantry under respiratory gating through
one to three ports with coplanar angles.(20) During each treat-
ment session, the positional relationship between the center of
the irradiated field and the implanted fiducial marker was
examined using the orthogonal fluoroscopy unit attached to the
treatment unit. Reported doses are expressed in gray equiva-
lents (GyE), defined as the proton dose corrected by its relative
biological effectiveness. The relative biological effectiveness
value of the proton beam was 1.1.
Three irradiation protocols were used for PBT, depending on
tumor location. The feasibility of each protocol has been
already evaluated and confirmed in our previous report.(21) For
the gastrointestinal (GI) protocol, a total dose of 77.0 GyE in
35 fractions was administered for tumors located within 2 cm
of a digestive organ. In order to reduce gastrointestinal adverse
events, the target field was cut by using multileaf collimators
from the middle of treatment.(22) For the hilar protocol, 72.6
GyE in 22 fractions was administered for tumors located
within 2 cm of the porta hepatis. For the standard protocol,
66.0 GyE in 10 fractions was administered for peripheral
tumors located more than 2 cm from both the GI tract and
porta hepatis.(21) All patients received PBT for 5 days each
week.
Follow-up and evaluation. Abdominal CT or MRI images
and the serum tumor markers AFP and DCP were evaluated
every 2–4 months after PBT for patients without disease pro-
gression. When progression was suspected based on imaging
or tumor marker examinations, patients were followed up at
shorter intervals. Disease progression was evaluated according
to the Response Criteria in Solid Tumors (RECIST) version
1.0. Local progression was defined as enlargement of the tar-
geted HCC and/or new lesions that occurred in the irradiated
field or its boundary. When the disease progression was found,
appropriate therapies were given. Toxicities were graded
according to the National Cancer Institute Common Terminol-
ogy Criteria for Adverse Events (version 2.0).
Statistical analysis. Overall survival (OS), progression-free
survival (PFS), and local tumor control (LTC) were estimated
using the Kaplan–Meier method. The survival period was
defined as the time between PBT initiation and the event date
(any death for OS and any death or disease progression for
PFS). The LTC period was defined as the time between PBT
initiation and local progression in the irradiated field. Patients
without an event were censored at the date of the last event-
free confirmation. Differences in survival or LTC times
between groups were evaluated using the log-rank test. Factors
affecting survival were identified by multivariate analysis using
the Cox proportional hazards model. A P-value < 0.05 was
considered statistically significant. All statistical analyses were
performed using SPSS 21.0 statistical software (IBM, Armonk,
NY, USA).
Results
Patients. Between January 2002 and December 2009, 550
patients with HCC were treated using PBT at our hospital.
Among them, 135 patients had previously untreated HCC, and
131 met the eligibility criteria. Two patients withdrew consent
immediately after PBT. In total, 129 patients were followed
and analyzed. The number of patients who received GI proto-
col, hilar protocol, and standard protocol were 30, 45, and 54,
respectively.
Patient and tumor characteristics are shown in Table 1. The
median age was 72 years. One-fifth of the patients had severe
comorbidities, such as cardiovascular disease, chronic pul-
monary disease, cerebrovascular disease, renal failure, active
infectious disease, double cancers, and intractable disease, and
12% patients had tumor thrombi that extended to the first
branch or main trunk of the portal vein (Vp3/4) or inferior
vena cava (IVC). The numbers of patients with very early
stage (0), early stage (A), intermediate stage (B), and advanced
stage diseases (C) according to BCLC staging were 9, 21, 34,
and 65, respectively.
Tumor control and survival. All 129 patients completed PBT
without experiencing severe complications. No treatment-
related deaths were observed. The median patient observation
period was 55 months (95% confidence interval [CI], 43–
67 months). Fifty-eight patients died during the study period
due to HCC (n = 25), liver failure (n = 9), non-liver-related
disease (n = 16), or unknown reasons (n = 8). Local progres-
sion was observed in 12 patients. Disease progression at any
site was observed in 70 patients. As for subsequent treatments
after tumor progression, 16 patients were treated with TACE,
13 patients were treated with PBT, eight patients were treated
with RFA, two patients were treated with percutaneous ethanol
injection therapy, one patient was treated with RT, one patient
was treated with hepatic arterial infusion chemotherapy, and
19 patients were treated with the best supportive care alone.
The treatments for the remaining 10 patients were unknown.
No patients received hepatectomy or liver transplantation.
The 5-year LTC rates were 94% (95% CI, 82–100%) for 0/
A stage, 87% (95% CI, 75–99%) for B stage, and 75% (95%
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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CI, 58–92%) for C stage (P = 0.228) (Fig. 1a). The 5-year
PFS rates were 28% (95% CI, 9–46%) for 0/A stage patients,
23% (95% CI, 8–38%) for B stage patients, and 9% (95% CI,
0–18%) for C stage patients (P = 0.057) (Fig. 1b). The median
PFS times were 23 months (95% CI, 12–34 months) for 0/A
stage patients, 22 months (95% CI, 14–31 months) for B stage
patients, and 16 months (95% CI, 14–18 months) for C stage
patients. The 5-year OS rates were 69% (95% CI, 49–89%) for
Table 1. Clinical characteristics of patients and tumors
Total (n = 129) BCLC 0/A (n = 30) BCLC B (n = 34) BCLC C (n = 65)
Age (years)
Median (range) 72 (39–86) 72 (46–81) 69 (39–82) 74 (57–86)
≧75 years, n (%) 50 (38.8) 11 (36.7) 7 (20.6) 32 (49.2)
Gender, n (%)
Male 86 (66.7) 21 (70) 27 (79.4) 38 (58.5)
Female 43 (33.3) 9 (30) 7 (20.6) 27 (41.5)
Etiology, n (%)
HCV infected 95 (73.6) 25 (83.3) 21 (61.8) 49 (75.4)
HBV infected 7 (5.4) 3 (10.0) 2 (5.9) 2 (3.1)
Other 19 (14.7) 0 (0) 9 (26.5) 10 (15.4)
Unknown 8 (6.2) 2 (6.7) 2 (5.9) 4 (6.2)
PS, n (%)
0 70 (54.3) 30 (100) 34 (100) 6 (9.2)
1 50 (38.8) 0 (0) 0 (0) 50 (76.9)
2 9 (7.0) 0 (0) 0 (0) 9 (13.8)
Platelet count (9 104/mm3)
Median (range) 11.7 (2.6–40.7) 11.0 (3.3–35.0) 13.4 (3.7–40.7) 11.5 (2.6–28.1)
<10 9 104/mm3, n (%) 41 (31.8) 13 (43.3) 8 (23.5) 20 (30.8)
≧10 9 104/mm3, n (%) 84 (65.1) 15 (50) 26 (76.5) 43 (66.2)
Unknown 4 (3.1) 2 (6.7) 0 (0) 2 (3.1)
Serum AFP (ng/mL)
Median (range) 27.5 (2–115,591) 25.0 (3–9,535) 34.5 (2–13,055) 29.5 (2–115 591)
<20 ng/mL, n (%) 51 (39.7) 13 (43.3) 15 (44.1) 23 (35.4)
≧20 ng/mL, n (%) 77 (59.5) 17 (56.7) 19 (55.9) 41 (63.1)
Unknown 1 (0.8) 0 (0) 0 (0.0) 1 (1.5)
Serum DCP (mAU/mL)
Median (range) 76 (6–206,190) 25 (8–3,676) 146 (6–46,819) 135 (10–206 190)
<100 mAU/mL, n (%) 67 (52.7) 25 (83.3) 14 (41.2) 28 (43.1)
≧100 mAU/mL, n (%) 59 (45.0) 4 (13.3) 20 (58.8) 35 (53.8)
Unknown 3 (2.3) 1 (3.3) 0 (0) 2 (3.1)
Child–Pugh class, n (%)
A 101 (78.3) 24 (80) 32 (94.1) 45 (69.2)
B 28 (21.7) 6 (20) 2 (5.9) 20 (30.8)
Tumor no., n (%)
1 96 (74.4) 22 (73.3) 23 (67.6) 51 (78.5)
2 23 (17.8) 8 (26.7) 6 (17.6) 9 (13.8)
≧3 10 (7.8) 0 (0) 5 (14.7) 5 (7.7)
Maximum tumor size, n (%)
Median (range) 39 (10–135) 22 (10–30) 42 (32–86) 40 (15–135)
≦3 cm 50 (38.8) 30 (100) 0 (0) 20 (30.8)
>3 cm 79 (61.2) 0 (0) 34 (100) 45 (69.2)
Tumor thrombi, n (%)
Vp 0, 1 112 (86.8) 30 (100) 34 (100) 48 (73.8)
Vp 2 2 (1.6) 0 (0.0) 0 (0.0) 2 (3.1)
Vp 3 6 (4.7) 0 (0.0) 0 (0.0) 6 (9.2)
Vp 4 7 (5.4) 0 (0.0) 0 (0.0) 7 (10.8)
IVC 2 (1.6) 0 (0.0) 0 (0.0) 2 (3.1)
Protocol, n (%)
Standard 54 (41.9) 14 (46.7) 17(50) 23 (35.4)
Hilar 45 (34.9) 9 (30) 14 (41.2) 22 (33.8)
Gastrointestinal 30 (23.3) 7 (23.3) 3 (8.8) 20 (30.8)
Serious non-liver-related diseases, n (%)
Yes 26 (20.2) 2 (6.7) 7 (20.6) 17 (26.2)
No 103 (79.8) 28 (93.3) 27 (79.4) 48 (73.8)
AFP, alpha-fetoprotein; DCP, des-gamma-carboxy prothrombin; HBV, hepatitis B virus; HCV, hepatitis C virus; PS, Eastern Cooperative Oncology
Group performance status.
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0/A stage patients, 66% (95% CI, 48–84%) for B stage
patients, and 25% (95% CI, 11–40%) for C stage patients
(P < 0.001) (Fig. 1c). The median OS times were
92 months (95% CI, 44–141 months) for 0/A stage patients,
70 months (95% CI, 56–83 months) for B stage patients, and
39 months (95% CI, 18–60 months) for C stage patients.
There were significant differences in OS between 0/A stage
and C stage patients (P = 0.002) as well as between B stage
and C stage patients (P = 0.005). The LTC and OS rates in 15
patients with the extended tumor thrombi (Vp 3/4 or IVC)
were 90% (95% CI, 71–100%) and 34% (95% CI, 9–59%) at
5 years, respectively. The median OS for those patients was
50 months (95% CI, 12–88 months).
Factors affecting local tumor control and survival. Multivariate
analysis results for LTC and OS are shown in Table 2. There
was no significant factor predictive for LTC. On the other
hand, PS was the only significant prognostic factor for OS.
The median OS times of the patients with PS0, PS1, and PS2
were 74 months (95% CI, 47–100 months), 45 months (95%
CI, 23–67 months), and 18 months (95% CI, 14–23 months),
respectively (Fig. 2).
Although maximum tumor size and vascular involvement
are commonly reported prognostic factors for OS, neither fac-
tor was identified in present study (Table 2). LTC rate for
HCC <3 cm vs. HCC ≥3 cm was 81% (95% CI 66–96) vs.
86% (95% CI 77–96) at 5 years (P = 0.85), and OS was 57%
(95% CI 39–75) vs. 43% (95% CI 30–57) at 5 years
(P = 0.16). The results of multivariate analysis did not change
when we used a tumor diameter cutoff of 5 cm.
Figure 3 shows CT images of a successfully treated 81-year-
old woman with a large HCC (maximum diameter of 120 mm)
in the right hepatic lobe with a hepatic venous tumor throm-
bus, which reached the right cardiac atrium through the IVC
(Fig. 3a). She was treated with PBT targeting the main tumor
and tumor thrombus (Fig. 3b). Irradiation of 72.6 GyE in 22
fractions was administered for 30 days. The main tumor and
tumor thrombus markedly shrunk, and the IVC tumor throm-
bus disappeared 2 months after the completion of PBT
(Fig. 3c). She did not have remarkable adverse event except
for mild and transient radiation pneumonitis 12 month after
PBT. She survives for more than 9 years without any progres-
sion of HCC.
Toxicities and complications. No patients had severe compli-
cations due to PBT or adverse events higher than grade 2,
except for hematologic abnormalities. Hematologic toxicities
were difficult to assess the relation to PBT, because cirrhotic
Fig. 1. Kaplan–Meier curves of LTC, PFS, and OS according to BCLC stage in previously untreated HCC patients treated with PBT. Kaplan–Meier
curves of the local tumor control (a), progression-free survival (b), and overall survival (c). BCLC staging: stage 0/A stage (solid line; n = 30), B
stage (dotted line; n = 34), and C stage (broken line; n = 65). BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular carcinoma; LTC, local
tumor control; OS, overall survival; PBT, proton beam therapy; PFS, progression free survival.
Table 2. Multivariate analysis using the cox regression model for
LTC and OS
LTC OS
HR (95% CI) P HR (95% CI) P
Age (years)
<75 vs. ≧75 0.57 (0.13–2.62) 0.472 1.62 (0.84–3.13) 0.148
Gender
Female vs. Male 1.43 (0.32–6.46) 0.643 1.22 (0.63–2.34) 0.559
Etiology
Non-HCV vs. HCV 0.49 (0.07–3.26) 0.460 1.23 (0.54–2.80) 0.619
PS
0 vs. 1, 2 3.57 (0.75–17.0) 0.111 2.16 (1.08–4.32) 0.030
Platelet (9 104/mm3)
≧10 vs. <10 0.57 (0.09–3.57) 0.544 1.57 (0.83–2.98) 0.168
AFP (ng/mL)
<20 vs. ≧20 2.36 (0.55–10.0) 0.246 1.36 (0.74–2.51) 0.325
DCP (mAU/mL)
<100 vs. ≧100 0.15 (0.02–1.09) 0.061 1.47 (0.77–2.80) 0.238
Child–Pugh class
A vs. B 0.71 (0.10–5.34) 0.743 1.80 (0.78–4.13) 0.168
No. tumors
Single vs. Multiple 1.31 (0.29–6.05) 0.727 1.07 (0.55–2.09) 0.838
Tumor size (cm)
≦3 vs. >3 2.33 (0.42–12.8) 0.330 1.32 (0.70–2.49) 0.397
Tumor thrombi
Vp0/1 vs. Vp2/3/4,
IVC
0.85 (0.08–9.25) 0.894 0.85 (0.38–1.89) 0.682
Protocol
Standard or Hilar
vs. GI
2.89 (0.61–13.7) 0.180 0.96 (0.48–1.90) 0.904
Bold text indicates the statistically significant difference with a
P-value.
AFP, alpha-fetoprotein; DCP, des-gamma-carboxy prothrombin; GI,
gastrointestinal; HCV, hepatitis C virus; IVC, inferior vena cava; LTC,
local tumor control; OS, overall survival; PS, Eastern Cooperative
Oncology Group-performance status.
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patients usually have pancytopenia due to splenomegaly.
Indeed, 20% of the patients had grade 2 (<75 000/mm3) and
5.5% grade 3 (<50 000/mm3) thrombocytopenia before PBT.
However, no patient required a blood transfusion or PBT ces-
sation during treatment. Radiation dermatitis was common, but
no patient had grade 3 or higher dermatitis.
Discussion
Proton beam therapy exhibited excellent long-term efficacy
and good safety in untreated patients with localized HCC that
could be covered within the irradiation field. Our survival
results are consistent with those in the BCLC staging
report.(23) PBT may be beneficial not only in patients with
operable HCC but also in those with operation risks due to
comorbidities and with inoperable advanced HCC.
All LTC duration, PFS, and OS showed very similar trends
decreasing in accordance with advanced stage of the BCLC.
These were compatible with those in previous published reports
for the BCLC stage.(23,24) The present study of treatment-naive
patients with HCC confirmed that PBT yielded good LTC, as
seen in previous reports for PBT.(11,12,18) The 5-year OS (69%)
in patients with BCLC 0/A stage disease was comparable to that
reported for patients who underwent hepatectomies and local
ablative therapies, such as RFA.(23–26) These results indicate that
PBT can be considered an additional curative treatment option
for patients with HCC. Although our PBT results seem inferior
to those of liver transplantation within the Milan criteria,(27) the
majority of our patients were not eligible for liver transplanta-
tion because of their advanced age (median, 72 years), poor PS
(PS ≥ 1; 46%), or severe comorbidities (20%). In fact, there are
many HCC patients who refuse surgery or cannot receive it.
Advanced age was significantly associated with higher mortality
rates following hepatic resection or RFA in a large Japanese
national survey of HCC patients.(28) PBT would be a promising
treatment for such patients because of its low invasiveness. The
subsequent treatments with multimodality for the recurrent
lesions contribute on OS prolongation. Taking these together
with our present results into consideration, it is suggested that
initial PBT could achieve good LTC safely and this would rather
favorably influence the subsequent treatment outcome.
Multivariate analysis showed no significant factor affecting
LTC rate of PBT for HCC. This is a unique virtue of PBT
because tumor diameter is usually the risk factor of local
recurrence. The outcomes for patients with large HCCs are
generally worse because of the aggressive malignant behavior,
which is characterized by potential metastases and vascular
Fig. 2. Kaplan–Meier curves of OS according to PS in previously
untreated HCC patients treated with PBT. PS 0 (solid line; n = 70), PS 1
(dotted line; n = 50) and PS 2 (broken line; n = 9). HCC, hepatocellular
carcinoma; OS, overall survival; PBT, proton beam therapy; PS, Eastern
Cooperative Oncology Group performance status.
(a) (b) (c)
Fig. 3. Computed tomography (CT) images of an 81-year-old woman with advanced HCC involving a massive tumor thrombus in the IVC.
Images were obtained before PBT (a), during isodose distribution of PBT (b), and 2 months after the completion of PBT (c). PBT demonstrated
marked regression of both the main tumor and tumor thrombus (arrows). Isodose distribution is shown using contour lines (red line, 90% iso-
dose; blue line, 10% isodose). HCC, hepatocellular carcinoma; IVC, inferior vena cava; PBT, proton beam therapy.
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invasions. Microsatellite lesions are associated with approxi-
mately 50% of HCCs, including the smaller ones (2.5–
5.0 cm), and those tumors cannot always be resected during
surgery or ablated using RFA for anatomical and technical rea-
sons.(29,30) By contrast, PBT can target tumors, including
microsatellite lesions, by securing adequate safety irradiation
margins, and this may account for the high LTC rate for
patients with large HCCs.
Performance status was the only significant predictor of OS
by multivariate analysis, and PS may be a good prognostic
indicator in the HCC patients treated with PBT as well as
other cancer patients. Although Child–Pugh score is generally
reported as a prognostic factor of HCC patients, the score was
not selected as a significant prognostic factor in this study.
This might be because of confounding with PS, or simply
small sample size. Large tumor, which has been commonly
identified as a poor prognostic factor for HCC, did not affect
OS for patients treated with PBT in the present study. Similar
result was reported that tumor size did not affect OS of
patients who underwent hepatectomy for solitary HCC.(31)
PBT can cover the tumor with adequate margin and provide
good LTC, even if a large HCC exists astride both lobes of
the liver. For HCC with major vessel invasion, PBT can also
treat with adequate margin. Indeed, the patients advanced
HCC with major vessel tumor thrombi (Vp 3/4 or IVC)
demonstrated favorable survival. These results may be superior
to those for any other therapeutic options, including conven-
tional radiotherapy, sorafenib therapy, and hepatic arterial infu-
sion chemotherapy.(32,33) PBT has the potential to prolong
survival for some populations of HCC patients who cannot be
rescued by other therapies, as in the case shown in Figure 3.
Severe PBT adverse events were infrequent in the present
study. This differs greatly from conventional X-ray radiother-
apy, even including modern three-dimensional conformal RT
or SBRT, which still sometimes induces severe radiation-
induced liver disease and worsens liver function.(34,35) We
used three types of protocol, which were evaluated for efficacy
and safety in a previous report.(21) Although HCC adjacent to
alimentary tract are contraindicated for RT generally, PBT
with GI protocol could be completed in all patients without
severe adverse events. Further studies are required to clarify
which patients should be treated with modern RT techniques
or particle beam therapies, such as PBT and carbon ion beam
therapy.(36)
The major limitation of this study is a study including a
selection bias of patients with heterogeneous background. Most
subjects were patients introduced to our hospital for PBT,
because they refused surgery or conventional interventional
radiotherapy. To improve this bias, we analyzed outcomes of
patients classified according to BCLC stages, and compared
these results with the contemporary large-scale nationwide fol-
low-up study in Japan.(26) The long-term high LTC rates for
patients of each HCC stage suggest that PBT has promising
therapeutic potential. The downside of PBT is that there are
small numbers of facilities where it can be administered
because of high construction and maintenance costs, and as
such, the treatment is expensive (3 million yen in our hospi-
tal). This has made it difficult to generalize PBT into clinical
practice and conduct large multicenter comparative studies
using this modality. However, the number of PBT facilities
has increased gradually in recent years, and its associated costs
are decreasing.
In conclusion, PBT achieved long-term tumor control with
less toxicity. PBT is a viable treatment option for localized
HCC, and we now plan a multicenter controlled study compar-
ing PBT and hepatectomy.
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